GlassScriptPrepare for your visit
Boyd Taylor Hehn
Pulmonary Disease · Philadelphia, PA · NPI 1134212129
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$156,787.22
in general payments reported to CMS, 2019-2025 · $20K in 2025
The $20K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Who reported paying
General payments only, top 6 by amount.
- Glaxosmithkline, LLC. $101,165.15
- Astrazeneca Pharmaceuticals LP $42,289.28
- Ethicon INC. $7,457.02
- Covidien LP $3,056.31
- Pulmonx Corporation $1,856.87
- Grifols USA, LLC $285.47
Drugs and devices associated with these payments
Breztri Arexvy Monarch Platform Pulmonx Chartis Tablet Console Chartis Catheter Zephyr Endobronchial Valve Zephyr Delivery Catheter Nucala Prolastin-C Liquid Aliya System Airsupra Symbicort
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Boyd Hehn listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/651913/boyd-taylor-hehn